Literature DB >> 23016581

Antiangiogenic function of antithrombin is dependent on its conformational variation: implication for other serpins.

Asim Azhar1, Poonam Singh, Qudsia Rashid, Asma Naseem, Mohammad Sazzad Khan, Mohamad Aman Jairajpuri.   

Abstract

Endogenous angiogenesis inhibitor that specifically decreases tumor cell proliferation can be used to treat cancer since angiogenesis is required at every step of tumor progression and metastasis. Endothelial cells are the main target for the antiangiogenic therapy because they are non-transformed and easily accessible to angiogenic inhibitors. Antithrombin functions as a principal plasma protein inhibitor of blood coagulation proteinases and belongs to the family of serine protease inhibitors (serpins) which have common mechanism of inhibition. Antithrombin acquires a potent antiangiogenic activity upon conversion of the native molecule to cleaved or latent conformation. Cleaved and latent preparations of bovine and human plasma derived antithrombin inhibits capillary endothelial cell proliferation and the growth of human SK-NAS neuroblastoma and Lewis lung carcinoma tumors in mice but not the native antithrombin's. The native form of antithrombin binds with high affinity to vascular heparan sulfate proteoglycans containing a specific pentasaccharide sequence and it is this cofactor interaction that activates antithrombin to maximal rate of thrombin inhibition. Upon inhibitory complex formation with target proteinases the antithrombin undergoes stressed to relaxed transformation and lose their high affinity for pentasacchride. Low affinity relaxed conformation with reduced heparin binding like cleaved and latent are antiangiogenic but native high affinity heparin binding stressed conformation is not, indicating the critical importance of heparin affinity in antithrombin antiangiogenic function. Based on evidence of interactions of the endothelial cell growth factors bFGF (basic fibroblast growth factor) and VEGF (vascular endothelial cell growth factor) with heparin like molecule in matrix, the possibility of antiangiogenic antithrombin to interfere with endothelial cell growth and angiogenesis through heparin mediated mechanism deserves serious consideration and investigation. It is also possible that cleaved and latent conformations with reduced affinity for heparins can also induce conformational change in the antithrombin which can open an epitope on the antithrombin surface for appropriate interactions on the endothelial surface for better antiangiogenic activity. This review illustrates the potential of antithrombin and other serpin family members as endogenous antiangiogenic proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23016581

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  4 in total

Review 1.  Clinical use and the Italian demand for antithrombin.

Authors:  Giancarlo M Liumbruno; Massimo Franchini; Monica Lanzoni; Fabio Candura; Stefania Vaglio; Samantha Profili; Liviana Catalano; Giuseppina Facco; Simonetta Pupella; Gabriele Calizzani; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Early anticoagulation therapy for severe burns complicated by inhalation injury in a rabbit model.

Authors:  Zhong-Hua Fu; Guang-Hua Guo; Zhen-Fang Xiong; Xincheng Liao; Ming-Zhuo Liu; Jinhua Luo
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

3.  RNA-Seq Analyses Reveal That Endothelial Activation and Fibrosis Are Induced Early and Progressively by Besnoitia besnoiti Host Cell Invasion and Proliferation.

Authors:  Alejandro Jiménez-Meléndez; Chandra Ramakrishnan; Adrian B Hehl; Giancarlo Russo; Gema Álvarez-García
Journal:  Front Cell Infect Microbiol       Date:  2020-05-15       Impact factor: 5.293

4.  Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.

Authors:  Kun Zhou; Jun Zhang; Zun-Rong Zheng; Yu-Zhen Zhou; Xun Zhou; Li-Da Wang; Bing Suo; Xiao-Feng Jiang; Pei-Jia Liu; Dong-Hua Wang
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.